Sep 29, 2025 01:08AM
Aug 5, 2025 04:07PM
May 7, 2025 04:11PM
Mar 6, 2025 09:45AM
Feb 27, 2025 04:10PM
Feb 18, 2025 08:01AM
Feb 18, 2025 08:00AM Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
Jan 12, 2025 08:04PM
Dec 4, 2024 04:55PM
Dec 4, 2024 04:55PM
Dec 4, 2024 03:49PM
Dec 3, 2024 06:50AM
Dec 2, 2024 08:02AM
Dec 2, 2024 08:00AM Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Nov 5, 2024 06:33AM
Nov 5, 2024 06:33AM
Nov 5, 2024 06:30AM
Oct 31, 2024 08:08AM
Sep 30, 2024 08:04AM
Sep 30, 2024 08:00AM
Sep 17, 2024 09:00AM Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Aug 28, 2024 07:00AM
Aug 1, 2024 04:10PM
Jul 24, 2024 07:00AM
May 13, 2024 08:03AM
May 13, 2024 08:00AM
May 8, 2024 04:15PM
May 6, 2024 04:05PM Merus N.V. (MRUS) Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno
May 6, 2024 04:05PM
Feb 28, 2024 04:15PM
Nov 2, 2023 04:12PM
Oct 15, 2023 07:58PM
Aug 7, 2023 04:26PM
Jul 5, 2023 04:01PM
Jul 5, 2023 04:01PM Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
Jul 5, 2023 04:01PM
Jun 29, 2023 04:30PM
Jun 29, 2023 04:30PM
Jun 29, 2023 04:30PM
May 4, 2023 04:25PM
Apr 14, 2023 11:12AM
Apr 14, 2023 11:10AM Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Apr 14, 2023 11:10AM
Feb 28, 2023 04:25PM
Feb 28, 2023 04:25PM
Jan 9, 2023 06:05AM
Jan 9, 2023 06:05AM
Jan 9, 2023 04:57AM
Jan 8, 2023 09:00AM Merus Provides 2023 Outlook
Jan 8, 2023 09:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All